

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**FOSUN 复星**

**復星國際有限公司**  
**FOSUN INTERNATIONAL LIMITED**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 00656)**

## **CHANGE OF DIRECTORS**

The Board announces the following change of directors of the Company:

1. Mr. Fan Wei has resigned as a non-executive director of the Company with effect from 10 July 2015;
2. Mr. Wu Ping has resigned as an executive director of the Company with effect from 10 July 2015;
3. Mr. Chen Qiyu has been appointed as an executive director of the Company with effect from 10 July 2015; and
4. Mr. Xu Xiaoliang has been appointed as an executive director of the Company with effect from 10 July 2015.

The board of directors (the “**Board**”) of Fosun International Limited (the “**Company**”) announces the following change of directors of the Company:

1. Mr. Fan Wei (“**Mr. Fan**”) has resigned as a non-executive director of the Company with effect from 10 July 2015;
2. Mr. Wu Ping (“**Mr. Wu**”) has resigned as an executive director of the Company with effect from 10 July 2015;
3. Mr. Chen Qiyu (“**Mr. Chen**”) has been appointed as an executive director of the Company with effect from 10 July 2015; and
4. Mr. Xu Xiaoliang (“**Mr. Xu**”) has been appointed as an executive director of the Company with effect from 10 July 2015.

Mr. Fan has resigned as a non-executive director of the Company with effect from 10 July 2015 due to health reasons; and Mr. Wu has resigned as an executive director and a senior vice president of the Company with effect from 10 July 2015 due to his appointment as a vice chairman of the supervisory board of Shanghai Fosun High Technology (Group) Co.,

Ltd. (“**Fosun Group**”). After his new appointment, Mr. Wu will also resign from his positions of director and senior vice president of Fosun Group.

Both Mr. Fan and Mr. Wu have confirmed that they have no disagreement with the Board and there is nothing relating to their resignation that needs to be brought to the attention of the shareholders of the Company. Mr. Fan and Mr. Wu will not hold any position in the Company after their resignation, except that Mr. Wu will remain as a vice chairman of the supervisory board of Fosun Group.

The Board would like to express its sincere gratitude to both Mr. Fan and Mr. Wu for their valuable efforts and contributions to the Company during their term of office with the Company.

**Details of the newly appointed directors are set out below:**

Mr. Chen, aged 43, is the vice president of the Company, an executive director and chairman of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (listed on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) with stock code: 02196 and Shanghai Stock Exchange with stock code: 600196). Mr. Chen is also a non-executive director and vice chairman of Sinopharm Group Co., Ltd. (listed on the Hong Kong Stock Exchange with stock code: 01099) and a director of Zhejiang D.A. Diagnostic Company Limited (listed on the Growth Enterprise Board of the Shenzhen Stock Exchange with stock code: 300244). Mr. Chen was a non-executive director of Shanghai Forte Land Co., Ltd.. Mr. Chen joined Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in April 1994 and was appointed a director in May 2005. Prior to joining the Group, Mr. Chen worked in Shanghai RAAS Blood Product Corporation, now known as Shanghai RAAS Blood Product Company Limited (listed on the Growth Enterprise Board of the Shenzhen Stock Exchange with stock code: 002252). Mr. Chen is the chairman of China Medical Pharmaceutical Material Association, a vice president of China Pharmaceutical Industry Research and Development Association, a vice council chairman of China Medicinal Biotechnology Association, a vice president of China Pharmaceutical Industry Association, the chairman of Shanghai Biopharmaceutical Industry Association and a council member of Shanghai Society of Genetics. Mr. Chen received a bachelor’s degree in genetics from Fudan University in July 1993 and an EMBA degree from China Europe International Business School in September 2005.

As at the date of this announcement, Mr. Chen is deemed to hold 4,023,000 shares of the Company.

Save as disclosed above, Mr. Chen does not hold any other directorship in any listed public company which securities are listed on any securities market in Hong Kong or overseas during the period of three years preceding the date of this announcement. Save as disclosed

above, as at the date of this announcement, Mr. Chen (i) does not hold any significant position in the Company or other members of the Company's group; (ii) does not have any relationships with any other directors, senior management or substantial or controlling shareholders of the Company; (iii) does not have, and/or is not deemed to have, any interest or short positions in any shares, underlying shares or debentures of the Company or its associated corporations (as defined under Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong); and (iv) does not have other major appointments or professional qualifications.

Mr. Chen has entered into a service contract with the Company with a fixed term of services for 3 years commencing from 10 July 2015, and is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Company's articles of association. Mr. Chen does not receive any salary for acting as the executive director of the Company.

There are no other matters which need to be brought to the attention of the shareholders of the Company regarding the appointment of Mr. Chen or is there any other information is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited ("**Listing Rules**").

Mr. Xu, aged 42, is a vice president of the Company. He is also the chairman of Shanghai Yuyuan Tourist Mart Co., Ltd. (listed on the Shanghai Stock Exchange with stock code: 600655), a non-executive director of Zhaojin Mining Industry Co., Ltd. (listed on the Hong Kong Stock Exchange with stock code: 01818) and Shanghai Zendai Property Limited (listed on the Hong Kong Stock Exchange with stock code: 00755). Mr. Xu was the senior assistant to the president of Fosun Group, the assistant general manager of Shanghai Forte Land Co., Ltd. and the chairman of Shanghai Resource Property Consultancy Co., Ltd.. Mr. Xu is a member of Shanghai Youth Federation and a vice chairman of China Real Estate Chamber of Commerce. Mr. Xu was successively awarded the "Shanghai 4 May Youth Medal" and "Shanghai Top Ten Youth Business People". Mr. Xu graduated from the Innova Education School of Singapore with a diploma in July 1995 and obtained his master's degree in business administration from the East China Normal University in January 2002.

As at the date of this announcement, Mr. Xu is deemed to hold 190,000 shares of the Company.

Save as disclosed above, Mr. Xu does not hold any other directorship in any listed public company which securities are listed on any securities market in Hong Kong or overseas during the period of three years preceding the date of this announcement. Save as disclosed above, as at the date of this announcement, Mr. Xu (i) does not hold any significant position within the Company and other members of the Company's group; (ii) does not have any

relationships with any other directors, senior management or substantial or controlling shareholders of the Company; (iii) does not have, and/or is not deemed to have, any interest or short positions in any shares, underlying shares or debentures of the Company or its associated corporations (as defined under Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong); and (iv) does not have other major appointments or professional qualifications.

Mr. Xu has entered into a service contract with the Company with a fixed term of services for 3 years commencing from 10 July 2015, and is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Company's articles of association. Mr. Xu is entitled to a remuneration of RMB2,580,000 per annum which is determined by the Board taking reference to his duties and responsibilities and the Company's remuneration policy. He is also entitled to an annual discretionary bonus determined by the internal regulation of the Company.

There are no other matters which need to be brought to the attention of the shareholders of the Company regarding the appointment of Mr. Xu or is there any other information is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to welcome Mr. Chen and Mr. Xu to join the Board.

By Order of the Board  
**Fosun International Limited**  
**Guo Guangchang**  
*Chairman*

Shanghai, the PRC, 10 July 2015

*As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Ding Guoqi, Mr. Qin Xuetao, Mr. Chen Qiyu and Mr. Xu Xiaoliang; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang and Mr. Yang Chao.*